Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Combined Chemotherapy Protocols. Found 132 abstracts

no pagination
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug;40(4):393-8.   PMCID: PMC5026539
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE. Phase III Randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). Journal of Clinical Oncology. 2017 Jul;35(19):2184-92.   PMCID: PMC5493050
Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Nov 15;123(22):4411-8.
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017 Jan;18(1):31-41.   PMCID: PMC5476941
Seabloom DE, Galbraith AR, Haynes AM, Antonides JD, Wuertz BR, Miller WA, Miller KA, Steele VE, Miller MS, Clapper ML, O'Sullivan MG, Ondrey FG. Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention. Cancer prevention research (Philadelphia, Pa). 2017 Feb;10(2):116-23.   PMCID: PMC5690483
Xu MJ, Chu C, Rubin S, Lin LL. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. Am J Clin Oncol. 2017 Dec;40(6):598-604.   PMCID: PMC4733581
Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016 Aug;39(4):340-5.   PMCID: PMC4177955
Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. The New England journal of medicine. 2016 Feb 25;374(8):738-48.   PMCID: PMC5081077
Guttmann DM, Li H, Sevak P, Grover S, Jacobson G, Feldman A, Rubin S, Chu C, Bhatia S, Elshaikh MA, Lin LL. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2016 Jan;26(1):141-8.
Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol. 2016 Aug;97(2):108-20.
Zhao S, Tang H, Yan D, Fan J, Sun H, Wen Y, Yu F, Cui F, Zhang D, Xue Y, Liu C, Yue B, Chen J, Wang J, Wang X, Zhang M, Yu Y, Jiang W, Liu X, Mi Y, Zhou Z, Qin X, Peng Z. DDA1 promotes stage IIB-IIC colon cancer progression by activating NFkappaB/CSN2/GSK-3beta signaling. Oncotarget. 2016 Apr 12;7(15):19794-812.   PMCID: PMC4991419
Barta SK. To be or not to be HIV+, that is no longer the question. Blood. 2015 Jul 09;126(2):124-6.
Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr;121(7):1032-9.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol. 2015 May;33(13):1482-90.   PMCID: PMC4404425
Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther. 2015 Jan;16(12):1710-9.   PMCID: PMC4847811
Marks EI, Brennan M, El-Deiry WS. Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. Cancer Biology & Therapy. 2015 Aug;16(8):1136-9.   PMCID: 4622690
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. The New England journal of medicine. 2015 Mar 05;372(10):923-32.   PMCID: 4405231
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 08;125(2):236-41.   PMCID: PMC4287635
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Combined Chemotherapy Protocols

Antineoplastic Combined Chemotherapy Protocols therapeutic use Middle Aged Female administration & dosage drug therapy Male pathology Aged mortality Adult Disease-Free Survival Survival Rate Treatment Outcome Neoplasm Staging adverse effects 80 and over Aged therapy metabolism prevention & control Fluorouracil Adenocarcinoma Carboplatin Doxorubicin Cyclophosphamide Disease Progression Prednisone blood Monoclonal Antibodies Retrospective Studies Lung Neoplasms Prognosis Rituximab analogs & derivatives Cohort Studies genetics Chemoradiotherapy Follow-Up Studies Paclitaxel Vincristine Large B-Cell Lymphoma-Diffuse Tumor Cell Line Carcinosarcoma Salvage Therapy Prospective Studies radiotherapy etiology Monoclonal Antibodies-Murine-Derived Colorectal Neoplasms Adjuvant Radiotherapy metastatic colorectal adenocarcinoma diagnosis secondary Adjuvant Chemotherapy methods chemically induced Risk Factors Tumor Biomarkers surgery Camptothecin Drug Dose-Response Relationship Young Adult doxorubicin CA-19-9 Antigen Kaplan-Meier Estimate complications Neoplasm Drug Resistance Neoplasm Invasiveness Local Neoplasm Recurrence Lymph Node Excision adverse effects Hysterectomy Brachytherapy Recurrence Small Cell Carcinoma Cyclooxygenase 2 Intention to Treat Analysis central nervous system involvement Glycogen Synthase Kinase 3 beta epidemiology Endometrioid Carcinoma Ca 19-9 Survival Analysis Western Blotting Pregnancy Rate HCT116 Cells Thiazolidinediones Vitamin D Deficiency Cisplatin Phenylurea Compounds Transitional Cell Carcinoma Leucovorin NF-kappa B Breast Neoplasms non-Hodgkin lymphoma central nervous system prophylaxis Non-Small-Cell Lung Carcinoma capecitabine use Spinal Injections consolidation Positron-Emission Tomography Proportional Hazards Models Pancreatic Neoplasms Hematopoietic Stem Cell Transplantation Taxoids Incidence Piperidines bladder cancer dosage Dinoprostone Nude Mice Tandem Mass Spectrometry Muscle Neoplasms ras Proteins Premenopause Celecoxib DNA-Binding Proteins gemcitabine plus cisplatin Enoxaparin biosynthesis drug effects therapeutic myc Genes Rectal Neoplasms Colonic Neoplasms Neoplastic Gene Expression Regulation Bevacizumab Radiotherapy Double-Blind Method Urinary Bladder Neoplasms statistics & numerical data hematopoietic cell transplantation (HCT) Quinazolines Heterologous Transplantation Thromboembolism Methotrexate neoadjuvant Pemetrexed Retreatment Protein Kinase Inhibitors 5-fu regorafenib diffuse large B-cell lymphoma (DLBCL) Postoperative Period Carcinoembryonic Antigen Gonadotropin-Releasing Hormone diffuse large B-cell lymphoma
Last updated on Friday, February 02, 2018